NASDAQConsumer StaplesHousehold & Personal ProductsSnapshot 2026-07-23
Reading UG? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
UG represents a durable compounder with a focus on steady growth and dividend payments. The current thesis is intact, with management successfully increasing sales and dividends while navigating a challenging environment.
The market currently prices UG as justified, reflecting a low fragility tier despite some concerns about execution quality. Valuation is considered cheap compared to peers, indicating that expectations are somewhat conservative.
Management's recent financial performance has been strong, with significant sales growth in both pharmaceuticals and cosmetic ingredients. However, the earnings quality is fragile, which may pose risks if guidance is cut in the near term.
The future of UG hinges on key factors such as guidance updates from management, inflation trends, and the performance of sector bellwethers like PG, UL, and CL. Positive developments in these areas could support continued growth.
Over the next 1 to 3 years, UG's stability and growth potential will depend on effective management execution and external economic conditions. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: The earnings report will provide key updates on revenue and profit trends. It will help assess management's growth strategy.
Confirms one read:Earnings report shows revenue growth and profit margins improving.
Confirms the other:The earnings report shows that revenue is down. Profit margins are also getting worse.
Why it matters: Stable or rising purchases from ASI show strong demand for cosmetic ingredients. This helps sales grow.
Confirms:ASI's purchases go up or stay the same compared to past quarters.
Disproves:ASI's purchases drop a lot compared to the last quarter.
Why it matters: GDP growth impacts overall economic health. Strong growth can boost demand for United-Guardian's products.
Confirms:GDP growth in the third estimate exceeds 2% for Q1 2026 on June 25.
Disproves:GDP growth is below 1% in the third estimate.
Why it matters: Changes in interest rates affect how much people spend and borrow. This changes demand for United-Guardian's products.
Confirms one read:The FOMC raised interest rates on June 17. This shows the economy is getting stronger.
Confirms the other:The FOMC keeps interest rates the same or lowers them. This shows the economy is weak.
Why it matters: Retail sales trends can impact United-Guardian's revenue. Strong sales may signal better demand for its products.
Confirms:Retail sales growth exceeds 0.5% month over month in the report on June 17.
Disproves:Retail sales growth is negative or below 0.5% month over month.
Why it matters: Keeping the dividend shows that the company cares about its shareholders. It also shows that management believes in the cash flow.
Confirms:Dividend per share remains at $0.25 or increases in Q2.
Disproves:Dividend per share decreases further from $0.25 in Q2.
Why it matters: Improving revenue growth would show that management's sales goals are on track. It would also signal better performance amid a mixed sector outlook.
Confirms:Q2 revenue grows year over year by more than 5% compared to Q1.
Disproves:Q2 revenue declines year over year or grows less than 5%.
Why it matters: Strong growth in pharmaceutical sales is key to overall revenue growth. It signals ongoing demand for Renacidin.
Confirms:Q2 pharmaceutical sales growth exceeds 20% year over year.
Disproves:Pharmaceutical sales growth falls below 10% year over year.
Why it matters: The next dividend announcement shows management wants to give value to shareholders. It also shows financial health.
Confirms one read:A dividend increase is announced after the payment on August 4.
Confirms the other:No dividend increase is announced after the payment on August 4.
